Favorable clinical course after early-intensive immunotherapy for new-onset refractory status epilepticus
Journal of Neurocritical Care. 2020;13(1):65-68 
A favorable outcome of intensive immunotherapies for new-onset refractory status epilepticus (NORSE)
Journal of Intensive Care. 2018;6(1):
Five cases of new onset refractory status epilepticus (NORSE) syndrome: Outcomes with early immunotherapy
Seizure. 2013;22(3):217-220
Early clinical features of new-onset refractory status epilepticus (NORSE) in adults
BMC Neurology. 2022;22(1):
Improved outcome on early immunotherapy in new onset refractory status epilepticus (NORSE). Experience in Qatar
Epilepsy & Behavior. 2019;101:106773
Refractory status epilepticus syndrome FIRES (febrile infection-related epilepsy syndrome) + NORSE (new-onset refractory status epilepticus): description of a rare clinical case
Neurology, Neuropsychiatry, Psychosomatics. 2019;11(4):153-155
A retrospective cohort study of new‐onset refractory status epilepticus (NORSE): clinical features, timing of immunotherapy and outcomes
Epileptic Disorders. 2022;24(5):867-876
New‐onset refractory status epilepticus as an early manifestation of multisystem inflammatory syndrome in adults after COVID‐19
Epilepsia. 2022;63(5):
New onset refractory status epilepticus (NORSE)
Seizure. 2019;68:72-78
Tozinameran
Reactions Weekly. 2022;1917(1):554-554